In CRC, cetuximab and panitumumab are approved for use in RAS wild-type patients only: for their use in patients with a BRAF mutation, only limited data are available from subgroup analyses of larger confirmatory studies (Table 1), as well as from retrospective case series derived from clinical routine data [22, 23]. Here, BRAF is linked to colorectal carcinoma.